ZTALMY — IMMEDICA PHARMA, approved 2025-10-16 (NDA215904).
629 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.